Health · 1 views
FDA support advances biomarker for earlier, more precise Parkinson's clinical trials
The Critical Path Institute released a regulatory endorsement stating that the alpha‑synuclein seed amplification assay (αSyn‑SAA) can be…
AI Summary
The Critical Path Institute released a regulatory endorsement stating that the alpha‑synuclein seed amplification assay (αSyn‑SAA) can be used as a susceptibility and risk biomarker in clinical trials for synucleinopathies. The endorsement was published in the Journal of Parkinson’s Disease and represents a milestone for the institute’s Critical Path for Parkinson’s consortium.
Read full article on Medical XpressAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow